LONDON (Alliance News) - LiDCO Group PLC on Monday said the US Food & Drug Administration granted 510k market clearance for its latest product, the LiDCOunity, a hemodynamic monitor that combines the company's technology into one platform.
LiDCO, which supplies equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are oxygenated, said approval was "key" to ensure it is able to offer its latest technology to surgeons and anaesthetists.
"The US is the world's single largest market for hemodynamic monitoring in high risk surgery and is expanding as hospitals implement Enhanced Recovery after Surgery (ERAS) and Perioperative Surgical Home programmes," Chief Executive Officer Matt Sassone said in a statement.
Shares in LiDCO were up 3.0% at 8.50 pence on Monday morning.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
